GSK,PFE,RHHBY -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Which Is the Best Hemophilia Stock to Buy Now?
    Motley Fool6 hours ago

    Which Is the Best Hemophilia Stock to Buy Now?

    New drugs to treat the rare bleeding disorder are on the way, but which drugmaker will come out ahead?

  • How to Invest in Diabetes Stocks
    Motley Fool20 hours ago

    How to Invest in Diabetes Stocks

    Here's everything you need to know about investing in the fast-growing diabetes market.

  • Label Expansion May Boost Opdivo’s Revenues in 2018
    Market Realist21 hours ago

    Label Expansion May Boost Opdivo’s Revenues in 2018

    Bristol-Myers Squibbs (BMY) is anticipating key data readouts from multiple phase 3 trials evaluating Opdivo in indications such as gastric cancer, head and neck cancer, small cell lung cancer, and hepatocellular carcinoma, by the end of 2019. On April 18, Bristol-Myers Squibb announced that the FDA had granted priority review for a supplemental biologics application (or sBLA) seeking approval for Opdivo in the third-line small cell lung cancer (or SCLC) indication. The Prescription Drug User Fee Act (or PDUFA) date for this application has been set for August 16.

  • Opdivo May Witness Decline in This Target Patient Population
    Market Realist23 hours ago

    Opdivo May Witness Decline in This Target Patient Population

    At end of Q1 2018, Bristol-Myers Squibb’s (BMY) Opdivo earned 40% of its revenues in the US market from the lung cancer indication, while the remaining US market revenues were attributable to demand for the drug in other tumor types. By the end of Q1 2018, the drug had managed to maintain its market share in the second-line lung cancer segment in the US.

  • Opdivo Continues to Be Key Growth Driver for Bristol-Myers Squibb
    Market Realistyesterday

    Opdivo Continues to Be Key Growth Driver for Bristol-Myers Squibb

    In the first quarter, Bristol-Myers Squibb’s (BMY) Opdivo witnessed sales close to $1.5 billion, driven by a robust rise in demand across the approved indications of lung cancer, renal cell carcinoma (or RCC), head and neck cancer, and melanoma. Further, the company is also witnessing robust uptake of Opdivo as adjuvant therapy for melanoma patients. To know more about Opdivo as an adjuvant melanoma therapy, please read Opdivo Could Be Key Revenue Driver for Bristol-Myers Squibb in 2018.

  • This Collaboration Is Expected to Boost Merck’s Long-Term Growth
    Market Realistyesterday

    This Collaboration Is Expected to Boost Merck’s Long-Term Growth

    Merck & Company (MRK) has entered into a global strategic oncology collaboration with Eisai for the worldwide codevelopment and co-commercialization of Eisai’s Lenvima. Merck and Eisai will jointly develop and commercialize Lenvima as a monotherapy and in combination with Keytruda.

  • CNBCyesterday

    No recession until late 2020, so keep buying stocks, Credit Suisse says

    A U.S. recession won't happen until the third quarter of 2020, and in the meantime stocks are a good bet, according to Credit Suisse analyst Andrew Garthwaite.

  • A Brief Overview of Merck’s First-Quarter Performance
    Market Realistyesterday

    A Brief Overview of Merck’s First-Quarter Performance

    Merck & Company (MRK) reported revenue of $10.0 billion in Q1 2018 compared to $9.4 billion in Q1 2017, which reflected a ~6% rise YoY (year-over-year) and a ~4% fall sequentially. In Q1 2018, Merck saw a ~2% positive impact from foreign exchange.

  • The Wall Street Journalyesterday

    [$$] The Heated Quest for Opioid Alternatives

    Rising abuse of prescription painkillers is intensifying a search for alternatives to addictive opioids. Despite that toll, opioids remain in widespread use because they are powerful painkillers, and many attempts to develop new therapies have failed. LLC, a company that conducts clinical trials and specializes in pain studies.

  • Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval
    Zacksyesterday

    Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval

    The Dow endured another volatile week marked by key geopolitical developments.

  • Pfizer’s Products with Declining Revenues in Q1 2018
    Market Realistyesterday

    Pfizer’s Products with Declining Revenues in Q1 2018

    Pfizer’s (PFE) portfolio includes some products that are losing market share due to competition from other products in the market. Enbrel, the blockbuster drug, reported a 14% decline to $506 million in the first quarter. BeneFix’s revenues declined 2% to $147 million in the first quarter, driven by a 13% decline in international sales to $79 million, offset by a 16% growth in US sales to $68 million.

  • 3 Dividend Stocks That Pay You Better Than ExxonMobil Does
    Motley Foolyesterday

    3 Dividend Stocks That Pay You Better Than ExxonMobil Does

    Not only do these three stocks pay you more, but these investors think they have better prospects, too.

  • Financial Timesyesterday

    [$$] Stocks to watch: Kingfisher, AstraZeneca, Imperial Brands, Roche

    distressed debt specialist Hilco Capital for a nominal sum. also gained after Wesfarmers of Australia, which trades under the Bunnings banner, warned that its exit from the UK would generate a £200m loss. “Critically, Homebase will miss the considerable buying muscle of Bunnings in Asia, and we would expect less aggressive pricing on seasonal products,” said Jefferies, which saw B&Q benefiting from reduced capital expenditure requirements and a “sharply improved” outlook for margins.

  • Reuters2 days ago

    Australian anti-trust watchdog loses appeal against Pfizer over Lipitor sales

    An Australian court dismissed an appeal by the nation's anti-trust watchdog in a case against Pfizer Inc (PFE.N) in which the regulator alleged the company had used its market power to limit competition for its cholesterol-lowering drug Lipitor. The Australian Competition and Consumer Commission (ACCC) said on Friday it was considering the judgment and remained committed to pursuing cases involving "misuse of market power". "The ACCC brought this appeal because it was concerned that Pfizer's use of its market position as supplier of the top selling branded atorvastatin immediately before generic products were able to enter the market harmed the competitive process and therefore consumers," Chairman Rod Sims said in a statement.

  • Reuters2 days ago

    Australian anti-trust watchdog loses appeal against Pfizer over Lipitor sales

    An Australian court dismissed an appeal by the nation's anti-trust watchdog in a case against Pfizer Inc in which the regulator alleged the company had used its market power to limit competition for its cholesterol-lowering drug Lipitor. The Australian Competition and Consumer Commission (ACCC) said on Friday it was considering the judgment and remained committed to pursuing cases involving "misuse of market power". "The ACCC brought this appeal because it was concerned that Pfizer's use of its market position as supplier of the top selling branded atorvastatin immediately before generic products were able to enter the market harmed the competitive process and therefore consumers," Chairman Rod Sims said in a statement.

  • The Wall Street Journal2 days ago

    [$$] Pfizer to Pay $24 Million to Settle Probe Into Copay Assistance Charities

    Pfizer Inc. has agreed to pay nearly $24 million to resolve allegations that it violated federal law by using a charity to pay Medicare patients’ out-of-pocket costs for the company’s prescription drugs, federal prosecutors said. The settlement, with the U.S. Attorney’s Office in Boston, resolves allegations stemming from an investigation into charities that help patients pay for prescription drugs using donations from pharmaceutical companies.

  • Reuters2 days ago

    Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe

    The U.S. Department of Justice said on Thursday that the civil settlement resolves allegations that Pfizer improperly used the Patient Access Network Foundation as a conduit to cover co-payment obligations of patients taking three Pfizer drugs. Pfizer's actions enabled the New York-based drugmaker to boost prices and revenue, violating the federal False Claims Act in a scheme that ran from 2012 to 2016, the department said.

  • Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe
    Reuters2 days ago

    Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe

    The U.S. Department of Justice said on Thursday that the civil settlement resolves allegations that Pfizer improperly used the Patient Access Network Foundation as a conduit to cover co-payment obligations of patients taking three Pfizer drugs. Pfizer's actions enabled the New York-based drugmaker to boost prices and revenue, violating the federal False Claims Act in a scheme that ran from 2012 to 2016, the department said.

  • Pfizer Used Charity to Mask Heart Drug Price Hikes, U.S. Says
    Bloomberg2 days ago

    Pfizer Used Charity to Mask Heart Drug Price Hikes, U.S. Says

    Pfizer Inc. used a “purportedly independent” charity to help it sharply raise the price of a heart drug, shielding patients from the increase while Medicare picked up the higher costs, the U.S. Justice Department said Thursday in a civil settlement announcement. Pfizer will pay about $24 million in the anti-kickback settlement, the government said in a statement.

  • MarketWatch2 days ago

    Pfizer to pay $23.85 million to settle kickback allegations

    The Department of Justice said on Thursday that global pharmaceutical company Pfizer, Inc. settled allegations that it used a foundation as a conduit to pay the copays of Medicare patients taking three Pfizer drugs, in violation of the False Claims Act, and will pay $23.85 million to resolve the claims. Under the Anti-Kickback Statute, pharmaceutical companies are prohibited from offering, directly or indirectly, any payment-which includes paying patients' copay obligations-to induce Medicare patients to purchase the company's drugs.

  • Pfizer's Tafamadis Gets Breakthrough Therapy Designation
    Zacks2 days ago

    Pfizer's Tafamadis Gets Breakthrough Therapy Designation

    Pfizer's (PFE) rare disease candidate, tafamidis, gets Breakthrough Therapy designation in the United States for the treatment of transthyretin cardiomyopathy.

  • Pfizer’s Growth Drivers in Q1 2018
    Market Realist2 days ago

    Pfizer’s Growth Drivers in Q1 2018

    As we’ve already seen, Pfizer’s (PFE) products are segregated into two segments: Innovative Health and Essential Health. These products were Pfizer’s growth drivers in the first segment: BMP2, Chantix/Champix, Eliquis, Genotropin, Ibrance, Lipitor, Norvasc, Sulperazon, Sutent, Xalkori, Xeljanz, Xtandi, and a few others.

  • The Performance of Roche’s Tarceva, Actemra, and Other Drugs
    Market Realist2 days ago

    The Performance of Roche’s Tarceva, Actemra, and Other Drugs

    Roche’s (RHHBY) Tarceva generated revenues of 141 million Swiss francs in the first quarter compared to 211 million Swiss francs in the first quarter of 2017, which reflected an ~32% YoY (year-over-year) CER (constant exchange rate) decline and a 31% sequential decline.

  • Reuters2 days ago

    Drug maker Pfizer to pay $23.85 mln to settle claims it paid kickbacks

    Drug maker Pfizer will pay $23.85 million to settle civil charges that it illegally paid kickbacks by using a foundation as a "conduit" to cover co-pay costs for Medicare patients taking three of the company's drugs, the U.S. Justice Department said Thursday. As part of the settlement, the company will also enter a corporate integrity agreement with the inspector general for the Department of Health and Human Services, which will require the company to implement new compliance measures.

  • InvestorPlace2 days ago

    3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More

    A month ago, Pfizer Inc. (NYSE:PFE) felt the sting of a somewhat surprising disappointment. Its biosimilar version of Herceptin, the popular breast cancer drug from Roche Holding AG (OTCMKTS:RHHBY), was rejected by the FDA.Biosimilar drugs are nearly-identical copies of a competitor’s product. It was a blow not just because Herceptin generated sales of more than $7 billion last year, but because it put the viability of Pfizer’s entire biosimilar program into question.